These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Use of bisphosphonates in cancer patients. Body JJ; Coleman RE; Piccart M Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784 [No Abstract] [Full Text] [Related]
4. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). van Breukelen FJ; Bijvoet OL; van Oosterom AT Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043 [TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in the treatment of malignant bone disease. Berenson JR; Lipton A Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate]. Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630 [TBL] [Abstract][Full Text] [Related]
7. Use of dichloromethylene diphosphonate in metastatic bone disease. Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257 [TBL] [Abstract][Full Text] [Related]
9. [Role of bisphosphonates in the treatment of tumoral osteolysis]. Claudepierre P; Puéchal X; Menkès CJ Ann Med Interne (Paris); 1995; 146(5):325-7. PubMed ID: 8526319 [No Abstract] [Full Text] [Related]
10. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):119S-123S. PubMed ID: 9273953 [No Abstract] [Full Text] [Related]
11. Bisphosphonates--role in cancer therapies. Mehrotra B J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811 [No Abstract] [Full Text] [Related]